Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report

short title: ADEM and COVID-19

Sara Esmaeili, MD, MPH, PhD, Mohammad Hossein Abbasi, MD, MPH, Mohammad Taghi Joghataei, Ph.D, Zahra Mirzaasgari, MD, Maziar Emamikhah, MD, Mahin Jamshidi Makiani, MD, Hossein Nazarian, MD

*eFiroozgar Clinical Research and Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran

bCellular and Molecular Research Center, Iran university of medical sciences, Tehran, Iran

cSchool of Advanced Technologies in Medicine, Iran University of Medical, Tehran, Iran

dDepartment of neurology, Iran university of medical sciences, Tehran, Iran

eAntimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran.

Corresponding authors: Zahra Mirzaasgari, Iran University of Medical Sciences, Tehran, Iran and Hossein Nazarian, Iran University of Medical Sciences, Tehran, Iran.

Email: md.h.nazarian@gmail.com

1Co-first Authors:

The Co-Author 1 and Co-Author 2 have had equal contribution to this manuscript.

Conflict of interest: The authors deny any conflict of interest in any terms or by any means during the study.

Sources of Funding: No funding was secured for this study.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate: Patient consent was obtained prior to the surgery.
Contributors’ Statement Page:

Dr. Sara Esmaeili and Dr. Mahin Jamshidi Makiani and Dr. Hossein Nazarian: conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript.

Dr. Mohammad Hossein Abbasi and Dr. Maziar Emamikhah: Designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript.

Dr. Mohammad Taghi Joghataei and Dr. Zahra Mirzaasgari: Coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

Availability of data and material: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Consent for publication: Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Research registration: N/A

Guarantor: Sara Esmaeili
Abstract

**Introduction and importance:** Neurological ailments are reported during and after SARS-COV-2 infection.

**Case presentation:** We report a 67-year-old Iranian man with COVID-19 infection and Acute Disseminated Encephalomyelitis (ADEM) whose neurological symptoms appeared before clinical and radiological pulmonary manifestations.

**Clinical Discussion:** COVID-19 can cause neurological complication without entering the CNS via para infectious inflammatory mechanisms.

**Conclusions:** This report shows that ADEM might be among primary presentations of COVID-19.

**Keywords:** COVID-19; ADEM; Acute disseminated encephalomyelitis; central nervous system; Brain; Neurologic

**Introduction:**
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 emerged as pandemic in 2020 which is commonly presented by fever and respiratory symptoms (1). With advancements in evidences, multi-organ dysfunction is also reported with the infection (2, 3). Neurological complications associated with central nervous system (CNS) and peripheral nervous system (PNS) such as encephalitis and Guillen Barre disease have been reported with the infection (3-5). Despite diverse CNS presentations, detection of virus in cerebrospinal fluid has been scarcely reported, indicating that various mechanisms are responsible for neurological manifestation of the disease [17]. In this report, we describe a rare presentation of COVID-19 as a result of multifocal injuries in a 67-year-old male patient.

**Case description:**
A 67-year-old male was presented to emergency department (ED) with decreased level of consciousness. Symptoms initiated with drowsiness, two days before admission. Past medical history was insignificant. At the time of referral, his body temperature was 37.1 °C. He was drowsy and could not speak consistently, and could not obey simple tasks. Deep tendon reflexes were brisk and plantar reflexes were upward. Magnetic resonance imaging (MRI) of brain revealed extensive
high signal lesions in T2W and FLAIR sequences on bilateral cerebral hemispheres, para ventricular and subcortical white matter, middle cerebellar peduncles, centrum semi vale, corpus callosum, the basal ganglia, thalami, midbrain, and pons. (Figure 1) Post-contrast MRI showed sparse enhancements on midpart of the midbrain and left parietal lobe (Figure 2) COVID-19 infection was suggested by positive nasopharyngeal RT-PCT test result. Contrast enhanced CT thorax scan was normal at the time of admission. One day after admission, loss of consciousness along with respiratory distress, ultimately leading to the requirement of endotracheal intubation and admission to intensive care unit (ICU). Spiral CT scan for chest revealed diffused bilateral patchy ground glass opacities in both lungs along with few subpleural consolidations, indicating COVID-19 (Figure 3). Patient did not have any previous viral infection based on his asymptomatic history. Laboratory results from admission showed elevated C-reactive protein (CRP) (106 mg/L) and ESR (44 mm/h). Prothrombin Time (PT), International normalized ratio (INR) and Partial Thromboplastin Time (PTT) were in normal. Lymphopenia was present. Cerebrospinal fluid (CSF) analysis was normal for cell count, glucose and protein. CSF was negative for SARS-COV-2 and other viruses including Epstein-Barr virus, herpes simplex, cytomegalovirus, varicella-zoster. No oligoclonal bands were present. Clinical and Image findings coupled with laboratory data, led to the diagnosis of Acute disseminated encephalomyelitis (ADEM) associated with COVID-19. Along with COVID-19 treatment, methylprednisolone 1 g IV daily for 5 days was instituted. Neurologic status was grossly unchanged. Thus, Intravenous Immunoglobulin (IVIG) 0.4 g/kg daily was administered for 5 more consecutive days after Methylprednisolone pulse therapy. The patient eventually died after 4 weeks of hospital admission due to worsening of his respiratory and neurologic conditions. The methods are stated in accordance with SCARE 2020 guidelines (6).

Discussion:
In this patient, the clinical presentation coupled with imaging characteristics is consistent with a diagnosis of an acute demyelinating event. Our patient was diagnosed with COVID-19 based on positive RT-PCR for SARS-CoV-2 virus on admission. Signs of lung involvement evolved only after CNS involvements. We hypothesize that SARS-CoV-2 infection might have been responsible
for the post-infectious demyelinating CNS lesions, an entity known to occur in conjunction to many viral infections, and is in the spectrum of ADEM. This report is important, because it suggests that ADEM might be among primary presentations of SARS-COV-2. Nevertheless, establishing a coincidence or a cause-and-effect relationship may not be easily possible. This similar to some reports wherein the neurological syndrome appeared before clinical and/or radiological pulmonary manifestations. In some instances, the obvious clinical pulmonary symptoms never developed [7, 16].

ADEM, also known as postinfectious encephalomyelitis, is an infrequent para-or postinfectious autoimmune complications.(7) It is mainly a disorder of children. However, few cases in adults have also been reported. Clinically, it is heterogenous by nature and generally causes multifocal neurologic deficits in an acute manner, which often progresses rapidly. Typical MRI lesions consists of FLAIR hyperintensities in deep white matter and at the grey/white matter interface. Post-contrast enhancement is not always detected and usually in the form of punctate or rim enhancing pattern. Restriction can be detected in DWI sequence, especially in early course of disease (8). ADEM, as an immune-mediated demyelinating monophasic disorder, typically presents between 2–4 weeks after viral infections or immunizations [8, 9] Thus, the temporal relationship between COVID-19 symptoms and the onset of ADEM seems to be shorter than the classical picture described for other viral infections.

Acute Hemorrhagic Leukoencephalitis (AHLE), as a severe form of ADEM has been also reported in a COVID-19 patient (9). ADEM and AHLE share similar histologic features, however, in our patient, size of the lesions, lack of hemorrhage in the images, and normal CSF analysis are all in favor of ADEM diagnosis rather than AHLE, although the natural history was as grave as AHLE. To our knowledge, ADEM has been reported in association with COVID-19 in a few children and adult patients (10-15). The prognosis of these patients has been mostly favorable. However, our case had a poor outcome because of severe pulmonary involvement and respiratory distress as a result of COVID-19. We believe the presentation of COVID-19 as ADEM, which was not reported previously, may imply the severity of viral and/or inflammatory multi-system COVID-19 infection and can be considered an index for poor outcome. However, large scale multi-center studies are required in this regard.
It is likely that more than one immune mechanism is involved in triggering ADEM in susceptible patients and the exact mechanism of ADEM in case of COVID-19 infection is largely hypothetical and needs further research.

One of the potential underlying mechanisms of ADEM in association with SARS-CoV-2 is the cytokine pathway activation, which is known to be involved in the pathology of ADEM. It has been stated to result from T cells affected by SARS-CoV-2 inducing a storm of cytokines, especially IL-6 (16-18). This results in sequences of immune responses that may play an important role in the pathogenesis of ADEM (19).

Other mechanisms being discussed elsewhere includes post-infectious inflammatory process leading to the production autoantibody production to neuronal antigens (20). This mechanism is stated as “molecular mimicry” whereby an infectious organism contains numerous epitopes mimicking the structure of endogenous myelin epitopes (21). Some of the T-cells points toward the infectious epitopes during an immune response against the entering organism. As an undesirable consequence, some T-cells become skilled at cross-reacting with self-myelin peptides (21). These cross-reactive T-cells grow in numbers in response to self-antigenic stimulation and release chemokines that further recruit added lymphocytes and macrophages to the site of activation all of which enhances the demyelination process and neuronal injury [7, 21]. Based on few histopathological studies (22), the corresponding mechanism has been noticed in six post-mortem patients in forms of lymphocytic panencephalitis and meningitis along with brainstem perivascular and interstitial inflammatory alteration with neuronal loss as major features [7, 21]. It has long been accepted that the term ADEM should not be utilized in cases of acute encephalitis, which are caused by direct invasion of the viruses into the CNS (7). Still, few evidence of direct viral invasion with supportive histopathological features have been claimed, albeit very rare (23, 24). It has been hypnotized that SARS-CoV-2 dictates tissue tropism using the angiotensin-converting enzyme type 2 (ACE-2) receptor to bind to cells. The ACE-2 receptor can be found in nervous system tissue as well as endothelial cells among tissues of many other organs (25, 26). In the current report, the COVID-19 RNA was not detected using CSF, using RT-PCR method, thereby this mechanism may not comply to this case.

In addition, some studies have showed vascular-thrombotic complications associated with COVID-19 infection [6]. Histopathological findings of the postmortem brain study of a patient with diagnosis of SARS-COV-2 without specific signs of ADEDM suggested a vascular origin.
with secondary myelin loss, and the neocortical microscopic infarcts identified raise the possibility of micro thromboembolic events, probably related to COVID-19 related complications. However, in that study, the clinical presentation of ADEM was not apparent and the biopsy solely resembled an acute disseminated encephalomyelitis (ADEM)-like histological appearance.

Since we did not perform a postmortem study, we cannot verify the exact reason, although the pattern of DWI and ADC-map sequences of brain MRI may suggest micro thromboembolic events. For treatment, high dose corticosteroid followed by IVIG seemed to be effective (12). However, controversy remains regarding the optimal treatment options including the use of high dose corticosteroids in viremic, and often lymphopenic patients. The potential risks of using IVIG for ADEM, in patients with pro-thrombotic risk factors such as elevated D-dimer levels should be taken into consideration (27). Since this condition is potentially associated with high mortality, ADEM should be taken into account as a serious possible complication of COVID-19 infection during pandemic and prompt treatment should be initiated.

Our understanding of the Para infectious neuropathology of SARS CoV-2 continues to evolve, but as a cause of devastating outcome in many patients that do survive, there must be special attention to the phenomenology, pathophysiology and treatment of CNS involvement in COVID-19 patients (28).

**Conclusion**

ADEM might be among the primary extra-pulmonary manifestation of COVID-19 infection. Special awareness is warranted in patients presenting with any possible neurological manifestation in the current pandemic situation to prevent mortality and severe morbidity.

**Abbreviations:**

- Central nervous system (CNS)
- Peripheral nervous system (PNS)
- Emergency department (ED)
- Magnetic resonance imaging (MRI)
- Intensive care unit (ICU)
- C-reactive protein (CRP)
- Prothrombin Time (PT)
- International normalized ratio (INR)
- Partial Thromboplastin Time (PTT)
- Cerebrospinal fluid (CSF)
Acute disseminated encephalomyelitis (ADEM)
Intravenous Immunoglobulin (IVIG)
Acute Hemorrhagic Leukoencephalitis (AHLE)
angiotensin-converting enzyme type 2 (ACE-2)

References:

1. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. 2020;382(18):1708-20.
2. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience. 2020;11(7):995-8.
3. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. The Lancet Neurology. 2020;19(9):767-83.
4. Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. Neurocritical care. 2020;1-10.
5. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;77(6):683-90.
6. Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. International journal of surgery (London, England). 2020;84:226-30.
7. Javed A, Khan O. Acute disseminated encephalomyelitis. Handbook of clinical neurology. 2014;123:705-17.
8. Marin SE, Callen DJ. The magnetic resonance imaging appearance of monophasic acute disseminated encephalomyelitis: an update post application of the 2007 consensus criteria. Neuroimaging clinics of North America. 2013;23(2):245-66.
9. Yong MH, Chan YFZ, Liu J, Sanamandra SK, Kheok SW, Lim KC, et al. A Rare Case of Acute Hemorrhagic Leukoencephalitis in a COVID-19 Patient. J Neurol Sci. 2020;416:117035.
10. Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM). Journal of neurology. 2020;267(10):2799-802.
11. Abdi S, Ghorbani A, Fatehi F. The association of SARS-CoV-2 infection and acute disseminated encephalomyelitis without prominent clinical pulmonary symptoms. J Neurol Sci. 2020;416:117001.
12. Afshar H, Yassin Z, Kalantari S, Aloosh O, Lotfi T, Moghaddasi M, et al. Evolution and resolution of brain involvement associated with SARS-CoV2 infection: A close Clinical - Paraclinical follow up study of a case. Multiple sclerosis and related disorders. 2020;43:102216.
13. Utukuri PS, Bautista A, Lignelli A, Moonis G. Possible Acute Disseminated Encephalomyelitis Related to Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2020.
14. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nature Reviews Neurology. 2020;16(11):636-44.
15. Demirci Otluoglu G, Yener U, Demir MK, Yilmaz B. Encephalomyelitis associated with Covid-19 infection: case report. British Journal of Neurosurgery. 2020;1-3.
16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033-4.
17. Alizadeh R, Aghsaieifard Z. Does COVID19 activates previous chronic pain? A case series. Ann Med Surg (Lond). 2021;61:169-71.
18. Vaziri-Harami R, Delkash P. Can l-carnitine reduce post-COVID-19 fatigue? Ann Med Surg (Lond). 2022;73:103145.
19. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. Journal of medical virology. 2020;92(6):552-5.
20. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, JI Macario A, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmunity reviews. 2020;19(8):102591.
21. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (New York, NY). 1985;230(4729):1043-5.
22. von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. The Lancet. 2020;395(10241):e109.
23. Ann Yeh E, Collins A, Cohen ME, Duffner PK, Faden H. Detection of Coronavirus in the Central Nervous System of a Child With Acute Disseminated Encephalomyelitis. 2004;113(1):e73-e6.
24. Espíndola OM, Brandão CO, Gomes YCP, Siqueira M, Soares CN, Lima MASD, et al. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development. International Journal of Infectious Diseases.
25. Berger JR. COVID-19 and the nervous system. Journal of NeuroVirology. 2020;26(2):143-8.
26. Aghsaieifard Z, Alizadeh R. The Role of Angiotensin-Converting Enzyme in Immunity: Shedding Light on Experimental Findings. Endocrine, Metabolic & Immune Disorders - Drug Targets(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders). 2022;22(1):6-14.
27. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104-20.
28. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinietti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140(1):1-6.

Figure1: T2 flare views, axial magnetic resonance imaging (MRI), showing multifocal T2 hyperintense lesions with sparse enhancement on bilateral cerebral hemispheres, periventricular and subcortical white matter, middle cerebellar peduncles, centrum semiovale, corpus callosum, the basal ganglia, thalami, midbrain and brainstem.
Figure 2: T1 postcontrast(gadolinium) views, axial magnetic resonance imaging (MRI), showing multifocal T2 hyperintense lesions with sparse enhancements on bilateral cerebral hemispheres para ventricular and subcortical white matter, middle cerebellar peduncles, centrum semiovale, corpus callosum, basal ganglia, thalami, midbrain and brain stem.

Figure 3: Chest CT scan shown ground glass opacities on the right middle lobe. There is also visible the reticular pattern on both lungs’ fields.
Some Para- and Post-infectious central nervous system (CNS) syndromes have been defined in cases of SARS-COV-2.

This report shows that ADEM might be the first presentation of Covid-19.

Special awareness is warranted in patients presenting with any possible neurological manifestation in the current pandemic situation.
International Journal of Surgery Case Reports

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated.

Please state any conflicts of interest
All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

The authors deny any conflict of interest in any terms or by any means during the study.

Please state any sources of funding for your research
All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

NONE

Ethical Approval

Research studies involving patients require ethical approval. Please state whether approval or exemption has been given, name the relevant ethics committee and the state the reference number for their judgement. Please give a statement regarding ethical approval that will be included in the publication of your article, if the study is exempt from ethical approval in your institution please state this.

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards

Consent

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must
include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients’ and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways, should be listed as contributors.

Dr. Sara Esmaeili and Dr. Mahin Jamshidi Makiani and Dr. Hossein Nazarian: conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript.

Dr. Mohammad Hossein Abbasi and Dr. Maziar Emamikhah: Designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript.

Dr. Mohammad Taghi Joghataei and Dr. Zahra Mirzaasgari: Coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

Registration of Research Studies

In accordance with the Declaration of Helsinki 2013, the Editors of IJS Case Reports require that reports that are ‘First in Man’ studies should be registered prospectively and failing that retrospectively. There are many places to register your First in Man case report:
Clinicaltrials.gov – for all human studies – free
Chinese Clinical Trial Registry chictr.org.cn – for all human studies - free
Researchregistry.com – for all human studies – charge
ISRCTN.com – for all human studies – charge
There are many national registries approved by the UN that can be found here

Elsevier does not support or endorse any registry.

1. Name of the registry:N/A
2. Unique identifying number or registration ID:N/A
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor
The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish

Sara Esmaeili
Annals of Medicine and Surgery

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

Please state any conflicts of interest
All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

The authors deny any conflict of interest in any terms or by any means during the study.

Please state any sources of funding for your research
All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

No funding was secured for this study

Ethical Approval

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed
consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Patients have a right to privacy. Patients’ and volunteers’ names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Not applicable

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

**Dr. Sara Esmaeili and Dr. Mahin Jamshidi Makiani and Dr. Hossein Nazarian:** conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript.

**Dr. Mohammad Hossein Abbasi and Dr. Maziar Emamikhah:** Designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript.

**Dr. Mohammad Taghi Joghataei and Dr. Zahra Mirzaasgari:** Coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

Registration of Research Studies

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at [http://www.researchregistry.com](http://www.researchregistry.com) to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: [ClinicalTrials.gov](http://ClinicalTrials.gov) or [ISRCTN](http://ISRCTN) or numerous other registries.
1. Name of the registry: N/a

2. Unique Identifying number or registration ID: N/A

3. Hyperlink to the registration (must be publicly accessible): N/A

**Guarantor**

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish

**Sara Esmaeili**